Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Jochen H. Lorch, MD, MS


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Director, Thyroid Cancer Center
  • Director, Endocrine Cancer Treatment Center
  • Physician
  • Associate Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Head and neck oncology
  • Thyroid cancer

Diseases Treated

Contact Information

  • Appointments877-332-4294 (new)
    617-632-3090 (follow-up)
  • Office Phone Number617-632-3090
  • Fax617-632-4448

Board Certification:

  • Hematology
  • Internal Medicine
  • Medical Oncology

Fellowship:

  • Martin-Luther-University, Halle, Germany, Hematology and Oncology
  • Northwestern University, Hematology and Oncology

Residency:

  • University of Munich, Radiology
  • University of Pennsylvania Health System, Internal Medicine

Medical School:

  • University of Regensburg, Germany

Research

Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Thyroid. 2021 Jan 19.
View in: PubMed

Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
View in: PubMed

Circulating tumor cell analysis in locally advanced and metastatic squamous cell carcinoma of the head and neck. Laryngoscope Investig Otolaryngol. 2020 Dec; 5(6):1063-1069.
View in: PubMed

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
View in: PubMed

Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component. Endocr Pathol. 2020 Sep; 31(3):283-290.
View in: PubMed

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 08 27; 383(9):825-835.
View in: PubMed

Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
View in: PubMed

A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 Jan 01; 109(1):134-144.
View in: PubMed

Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma. Histopathology. 2020 Aug; 77(2):314-320.
View in: PubMed

Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines. Ann Surg Oncol. 2021 Jan; 28(1):484-491.
View in: PubMed

Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma. Front Med (Lausanne). 2020; 7:198.
View in: PubMed

The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
View in: PubMed

A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. Histopathology. 2020 Apr; 76(5):707-713.
View in: PubMed

Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
View in: PubMed

Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
View in: PubMed

The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist. 2020 06; 25(6):505-514.
View in: PubMed

Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in: PubMed

Treatment of Aggressive Thyroid Cancer. Surg Pathol Clin. 2019 Dec; 12(4):943-950.
View in: PubMed

Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer. Surgery. 2020 01; 167(1):87-93.
View in: PubMed

Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid. 2019 09; 29(9):1255-1261.
View in: PubMed

Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid. 2019 05; 29(5):666-673.
View in: PubMed

Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019 05; 113:1-9.
View in: PubMed

The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer. J Endocr Soc. 2019 Apr 01; 3(4):791-800.
View in: PubMed

Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
View in: PubMed

IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
View in: PubMed

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018 10 01; 29(10):2141-2142.
View in: PubMed

Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer. JCI Insight. 2018 09 06; 3(17).
View in: PubMed

Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncol. 2018 10; 85:29-34.
View in: PubMed

Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
View in: PubMed

Lenvatinib-Associated Cervical Artery Dissections in a Patient with Radioiodine-Refractory Metastatic Papillary Thyroid Carcinoma. Front Med (Lausanne). 2017; 4:220.
View in: PubMed

Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018 02 22; 3(4).
View in: PubMed

Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after =1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018 01 19; 6(1):7.
View in: PubMed

Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553.
View in: PubMed

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
View in: PubMed

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
View in: PubMed

Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018 May; 47(5):568-577.
View in: PubMed

Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
View in: PubMed

Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
View in: PubMed

A case of primary secretory carcinoma of the thyroid with high-grade features. Histopathology. 2017 10; 71(4):665-669.
View in: PubMed

Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15; 123(14):2642-2650.
View in: PubMed

Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment. Oral Oncol. 2017 04; 67:77-82.
View in: PubMed

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017 04; 67:61-69.
View in: PubMed

Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
View in: PubMed

Successful Management of a Patient with Malignant Thyroid Teratoma. Thyroid. 2017 01; 27(1):125-128.
View in: PubMed

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clin Cancer Res. 2017 May 01; 23(9):2367-2373.
View in: PubMed

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct; 17(10):1374-1385.
View in: PubMed

Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. Oncologist. 2016 12; 21(12):1522-1529.
View in: PubMed

Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
View in: PubMed

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
View in: PubMed

Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
View in: PubMed

Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
View in: PubMed

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol. 2015 Oct; 1(7):907-15.
View in: PubMed

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back. Oncologist. 2015 Jul; 20(7):699-701.
View in: PubMed

Genomic analysis of metastatic cutaneous squamous cell carcinoma. Clin Cancer Res. 2015 Mar 15; 21(6):1447-56.
View in: PubMed

Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
View in: PubMed

Pilot study: Raman spectroscopy in differentiating premalignant and malignant oral lesions from normal mucosa and benign lesions in humans. Head Neck. 2015 Apr; 37(4):511-7.
View in: PubMed

Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. Virology. 2013 Jul 05; 441(2):107-13.
View in: PubMed

Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist. 2013; 18(3):288-93.
View in: PubMed

Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
View in: PubMed

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
View in: PubMed

Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery. 2012 Dec; 152(6):1142-9.
View in: PubMed

Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
View in: PubMed

Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012 Apr 01; 118(7):1811-7.
View in: PubMed

Serum antibodies to the HPV16 proteome as biomarkers for head and neck cancer. Br J Cancer. 2011 Jun 07; 104(12):1896-905.
View in: PubMed

Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
View in: PubMed

Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011 May; 22(5):1071-1077.
View in: PubMed

Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
View in: PubMed

Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010 Sep; 8(9):1217-26.
View in: PubMed

Role of EGF inhibitors in the treatment of recurrent or metastatic squamous cell head and neck cancer. Cancer Manag Res. 2009 Nov 03; 1:151-4.
View in: PubMed

Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
View in: PubMed

Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila). 2009 Sep; 2(9):776-81.
View in: PubMed

Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). J Clin Oncol. 2009 May 20; 27(15_suppl):6025.
View in: PubMed

Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii.
View in: PubMed

Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53.
View in: PubMed

Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res. 2007 Jan 15; 67(2):727-34.
View in: PubMed

Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem. 2004 Aug 27; 279(35):37191-200.
View in: PubMed

Loss of adhesion-regulated proteinase production is correlated with invasive activity in oral squamous cell carcinoma. Cancer. 2002 Dec 15; 95(12):2524-33.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Ratings

Top